• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在二级医院治疗的感染性心内膜炎:流行病学、临床、微生物学特征和预后,特别关注转至三级医院的患者。

Infective endocarditis treated in a secondary hospital: epidemiological, clinical, microbiological characteristics and prognosis, with special reference to patients transferred to a third level hospital.

机构信息

Ana Isabel Peláez Ballesta, Internal Medicine Department of the Hospital General Universitario Rafael Méndez (Lorca). Spain.

出版信息

Rev Esp Quimioter. 2022 Feb;35(1):35-42. doi: 10.37201/req/092.2021. Epub 2021 Nov 30.

DOI:10.37201/req/092.2021
PMID:34845895
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8790653/
Abstract

OBJECTIVE

To analyse the clinical and epidemiological characteristics and mortality-related factors of patients admitted to a secondary hospital with Infective Endocarditis (IE).

METHODS

Observational study of a cohort of patients who have been diagnosed with IE in a secondary hospital and evaluated in accordance with a pre-established protocol.

RESULTS

A total of 101 cases were evaluated (years 2000-2017), with an average age of 64 years and a male-to-female ratio of 2:1. 76% of the cases had an age-adjusted Charlson comorbidity index of >6, with 21% having had a dental procedure and 36% with a history of heart valve disease. The most common microorganism was methicillin-susceptible S. aureus (36%), with bacterial focus of unknown origin in 54%. The diagnostic delay time was 12 days in patients who were transferred, compared to 8 days in patients who were not transferred (p=0.07); the median surgery indication delay time was 5 days (IQR 13.5). The in-hospital mortality rate was 34.6% and the prognostic factors independently associated with mortality were: cerebrovascular events (OR 98.7%, 95% CI, 70.9-164.4); heart failure (OR 27.3, 95% CI, 10.2-149.1); and unsuitable antibiotic treatment (OR 7.2, 95% CI, 1.5-10.5). The mortality rate of the patients who were transferred and who therefore underwent surgery was 20% (5/25).

CONCLUSIONS

The onset of cerebrovascular events, heart failure and unsuitable antibiotic treatment are independently and significantly associated with in-hospital mortality. The mortality rate was higher than the published average (35%); the diagnostic delay was greater in patients for whom surgery was indicated.

摘要

目的

分析二级医院收治的感染性心内膜炎(IE)患者的临床和流行病学特征及与死亡率相关的因素。

方法

对二级医院确诊并按既定方案评估的 IE 患者队列进行观察性研究。

结果

共评估了 101 例患者(2000-2017 年),平均年龄为 64 岁,男女比例为 2:1。76%的病例Charlson 合并症指数调整后>6,21%有牙科手术史,36%有心脏瓣膜病史。最常见的微生物是耐甲氧西林金黄色葡萄球菌(36%),54%的细菌病灶来源不明。转院患者的诊断延迟时间为 12 天,而非转院患者为 8 天(p=0.07);手术指征的中位延迟时间为 5 天(IQR 13.5)。住院死亡率为 34.6%,与死亡率独立相关的预后因素为:脑血管事件(OR 98.7%,95%CI,70.9-164.4);心力衰竭(OR 27.3,95%CI,10.2-149.1);以及不适当的抗生素治疗(OR 7.2,95%CI,1.5-10.5)。转院且接受手术的患者死亡率为 20%(5/25)。

结论

脑血管事件、心力衰竭和不适当的抗生素治疗与院内死亡率独立且显著相关。死亡率高于已发表的平均水平(35%);手术指征患者的诊断延迟时间更长。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06c2/8790653/2f06f830261e/revespquimioter-35-35-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06c2/8790653/2612238cc2da/revespquimioter-35-35-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06c2/8790653/e44902da6120/revespquimioter-35-35-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06c2/8790653/2f06f830261e/revespquimioter-35-35-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06c2/8790653/2612238cc2da/revespquimioter-35-35-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06c2/8790653/e44902da6120/revespquimioter-35-35-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06c2/8790653/2f06f830261e/revespquimioter-35-35-g003.jpg

相似文献

1
Infective endocarditis treated in a secondary hospital: epidemiological, clinical, microbiological characteristics and prognosis, with special reference to patients transferred to a third level hospital.在二级医院治疗的感染性心内膜炎:流行病学、临床、微生物学特征和预后,特别关注转至三级医院的患者。
Rev Esp Quimioter. 2022 Feb;35(1):35-42. doi: 10.37201/req/092.2021. Epub 2021 Nov 30.
2
Time interval between infective endocarditis first symptoms and diagnosis: relationship to infective endocarditis characteristics, microorganisms and prognosis.感染性心内膜炎首发症状与诊断之间的时间间隔:与感染性心内膜炎特征、微生物及预后的关系
Ann Med. 2017 Mar;49(2):117-125. doi: 10.1080/07853890.2016.1235282. Epub 2016 Nov 3.
3
Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis.耐甲氧西林金黄色葡萄球菌与甲氧西林敏感金黄色葡萄球菌感染性心内膜炎的临床和预后差异。
BMC Infect Dis. 2020 Feb 21;20(1):160. doi: 10.1186/s12879-020-4895-1.
4
Epidemiologic and clinical characteristics of infective endocarditis: a single-center retrospective study in the Bronx, New York.感染性心内膜炎的流行病学和临床特征:纽约布朗克斯的单中心回顾性研究。
Infection. 2022 Oct;50(5):1349-1361. doi: 10.1007/s15010-022-01846-3. Epub 2022 May 25.
5
The changing landscape of infective endocarditis in South Africa.南非感染性心内膜炎的变化态势。
S Afr Med J. 2019 Jul 26;109(8):592-596. doi: 10.7196/SAMJ.2019.v109i8.13888.
6
Infective endocarditis post-transcatheter aortic valve implantation (TAVI), microbiological profile and clinical outcomes: A systematic review.经导管主动脉瓣植入术后感染性心内膜炎(TAVI)的微生物学特征和临床结局:系统评价。
PLoS One. 2020 Jan 17;15(1):e0225077. doi: 10.1371/journal.pone.0225077. eCollection 2020.
7
Incidence and risk factors for mortality in patients treated with combined ceftaroline for Gram-positive infective endocarditis.联合使用头孢洛林治疗革兰氏阳性感染性心内膜炎患者的死亡率及危险因素
Eur J Clin Microbiol Infect Dis. 2022 May;41(5):827-834. doi: 10.1007/s10096-022-04443-2. Epub 2022 Apr 18.
8
Impact of transfer to reference centres and surgical timing on the prognosis of surgically treated patients with infective endocarditis: a prospective multi-centre cohort study.转诊至权威中心和手术时机对感染性心内膜炎手术治疗患者预后的影响:一项前瞻性多中心队列研究。
Clin Microbiol Infect. 2023 Sep;29(9):1197.e1-1197.e7. doi: 10.1016/j.cmi.2023.06.003. Epub 2023 Jun 9.
9
Epidemiology, outcomes and prognosis of infective endocarditis in Northern Morocco.摩洛哥北部感染性心内膜炎的流行病学、结局和预后。
BMC Infect Dis. 2024 Jul 15;24(1):698. doi: 10.1186/s12879-024-09436-4.
10
Infective endocarditis in patients with bicuspid aortic valve: Clinical characteristics, complications, and prognosis.二叶式主动脉瓣患者的感染性心内膜炎:临床特征、并发症及预后
Enferm Infecc Microbiol Clin. 2017 Dec;35(10):645-650. doi: 10.1016/j.eimc.2016.06.017. Epub 2016 Aug 1.

引用本文的文献

1
Contemporary cohort study in adult patients with infective endocarditis.针对成年感染性心内膜炎患者的当代队列研究。
Braz J Infect Dis. 2025 May-Jun;29(3):104521. doi: 10.1016/j.bjid.2025.104521. Epub 2025 Apr 2.
2
Native Valve Infective Endocarditis with Severe Regurgitation: What Matters Is Heart Failure.伴有严重反流的自体瓣膜感染性心内膜炎:关键在于心力衰竭。
J Clin Med. 2024 Oct 18;13(20):6222. doi: 10.3390/jcm13206222.
3
Postoperative follow-up of 221 patients with infective endocarditis from Gaoligong mountain area of Yunnan in China: a retrospective, single-center, observational cohort study.

本文引用的文献

1
Importance of In-Hospital Prospective Registry and Infectious Endocarditis Heart Team to Monitor and Improve Quality of Care in Patients with Infectious Endocarditis.院内前瞻性登记和感染性心内膜炎心脏团队对监测和改善感染性心内膜炎患者护理质量的重要性。
J Clin Med. 2021 Aug 26;10(17):3832. doi: 10.3390/jcm10173832.
2
Current Challenges in the Management of Infective Endocarditis.感染性心内膜炎管理中的当前挑战
Front Med (Lausanne). 2021 Feb 22;8:641243. doi: 10.3389/fmed.2021.641243. eCollection 2021.
3
Predicting mortality in infective endocarditis: More light in a hazy landscape.
中国云南高黎贡山地区221例感染性心内膜炎患者的术后随访:一项回顾性、单中心观察性队列研究。
J Thorac Dis. 2024 May 31;16(5):3325-3337. doi: 10.21037/jtd-24-470. Epub 2024 May 29.
4
Sex-related disparities in the incidence and outcomes of infective endocarditis according to type 2 diabetes mellitus status in Spain, 2016-2020.根据西班牙 2016-2020 年 2 型糖尿病状况,比较感染性心内膜炎发病率和结局的性别差异。
Cardiovasc Diabetol. 2022 Sep 30;21(1):198. doi: 10.1186/s12933-022-01633-2.
预测感染性心内膜炎的死亡率:在模糊的领域中带来更多曙光。
Hellenic J Cardiol. 2020 Jul-Aug;61(4):253-255. doi: 10.1016/j.hjc.2020.09.013. Epub 2020 Sep 28.
4
The value of an "Endocarditis Team".“心内膜炎团队”的价值。
Ann Cardiothorac Surg. 2019 Nov;8(6):621-629. doi: 10.21037/acs.2019.09.03.
5
Infective endocarditis: an ongoing global challenge.感染性心内膜炎:一项持续存在的全球挑战。
Eur Heart J. 2019 Oct 14;40(39):3233-3236. doi: 10.1093/eurheartj/ehz694.
6
Clinical Practice Update on Infectious Endocarditis.临床感染性心内膜炎实践更新。
Am J Med. 2020 Jan;133(1):44-49. doi: 10.1016/j.amjmed.2019.08.022. Epub 2019 Sep 12.
7
Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study.感染性心内膜炎的临床表现、病因和结局。ESC-EORP EURO-ENDO(欧洲感染性心内膜炎)注册研究的结果:一项前瞻性队列研究。
Eur Heart J. 2019 Oct 14;40(39):3222-3232. doi: 10.1093/eurheartj/ehz620.
8
[Complications and prognosis of infective endocarditis].[感染性心内膜炎的并发症与预后]
Presse Med. 2019 May;48(5):532-538. doi: 10.1016/j.lpm.2019.04.002. Epub 2019 May 2.
9
Current Epidemiology and Outcome of Infective Endocarditis: A Multicenter, Prospective, Cohort Study.感染性心内膜炎的当前流行病学及结局:一项多中心、前瞻性队列研究
Medicine (Baltimore). 2015 Oct;94(43):e1816. doi: 10.1097/MD.0000000000001816.
10
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.成人感染性心内膜炎:诊断、抗菌治疗和并发症处理:美国心脏协会医疗保健专业人员科学声明。
Circulation. 2015 Oct 13;132(15):1435-86. doi: 10.1161/CIR.0000000000000296. Epub 2015 Sep 15.